Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a putative, uncharacterized noncoding RNA (natural antisense transcript) arising from the SHANK2 locus. Natural antisense transcripts (NATs) are a class of RNAs transcribed from the opposite strand of a protein-coding or noncoding gene; they often regulate their sense counterpart’s expression through transcriptional interference, RNA masking, chromatin remodeling, or double-stranded RNA mechanisms. The specific transcript “novel transcript, antisense to SHANK2” does not have any established function or role as a molecular target and is not classified as a receptor, enzyme, or other commonly targeted protein. Its presence in the genome annotation indicates it may play a regulatory role in modulating SHANK2 gene expression, which itself is involved in synaptic function and is implicated in neurodevelopmental disorders such as autism spectrum disorder; however, no direct functional or disease role for this antisense transcript has been established.
Not applicable (no drugs known to target this transcript)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to SHANK2 (ENSG00000286708).